These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8627851)

  • 1. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer.
    Cher ML; Stephenson RA; James BC; Carroll PR
    J Urol; 1996 May; 155(5):1674-7. PubMed ID: 8627851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relations of proliferative activities of gastric carcinoma cells to lymphatic involvement, venous invasion and prognosis.
    Wu YF; Xu HM; Chen JQ
    Chin Med J (Engl); 2004 Oct; 117(10):1530-5. PubMed ID: 15498378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry of prostate cancer: relationship of DNA content to survival.
    Stephenson RA; James BC; Gay H; Fair WR; Whitmore WF; Melamed MR
    Cancer Res; 1987 May; 47(9):2504-7. PubMed ID: 3567934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
    Khoo VS; Pollack A; Cowen D; Joon DL; Patel N; Terry NH; Zagars GK; von Eschenbach AC; Meistrich ML; Troncoso P
    Prostate; 1999 Nov; 41(3):166-72. PubMed ID: 10517874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer.
    Bazinet M; Hamdy SM; Bégin LR; Stephenson RA; Fair WR
    Prostate; 1992; 20(4):311-26. PubMed ID: 1376912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
    Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
    Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas.
    Stanton KJ; Sidner RA; Miller GA; Cummings OW; Schmidt CM; Howard TJ; Wiebke EA
    Am J Surg; 2003 Nov; 186(5):486-92. PubMed ID: 14599612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Zhang ZF; Bazinet M; Hamdy SM; Reuter VE
    J Urol; 1994 Apr; 151(4):914-9. PubMed ID: 8126824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
    J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
    Richardsen E; Uglehus RD; Due J; Busch C; Busund LT
    Cancer Epidemiol; 2010 Jun; 34(3):316-22. PubMed ID: 20409773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases.
    Coleman RL; Schink JC; Miller DS; Bauer KD; August CZ; Rademaker AW; Lurain JR
    Gynecol Oncol; 1993 Jul; 50(1):20-4. PubMed ID: 8349159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
    Cheng L; Pisansky TM; Sebo TJ; Leibovich BC; Ramnani DM; Weaver AL; Scherer BG; Blute ML; Zincke H; Bostwick DG
    Clin Cancer Res; 1999 Oct; 5(10):2820-3. PubMed ID: 10537347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
    Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
    J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization.
    Gburek BM; Kollmorgen TA; Qian J; D'Souza-Gburek SM; Lieber MM; Jenkins RB
    J Urol; 1997 Jan; 157(1):223-7. PubMed ID: 8976257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival predictors in patients with prostate adenocarcinoma with hormonal blockade.
    Angulo JC; Redondo C; Sánchez-Chapado M; Colás B; Ropero S; López JI
    Pathol Res Pract; 2016 Oct; 212(10):899-903. PubMed ID: 27502465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy.
    Cadeddu JA; Partin AW; Epstein JI; Walsh PC
    Urology; 1997 Aug; 50(2):251-5. PubMed ID: 9255297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow-cytometric DNA analysis of early stage adenocarcinoma of the cervix.
    Magtibay PM; Perrone JF; Stanhope CR; Katzmann JA; Keeney GL; Li H
    Gynecol Oncol; 1999 Oct; 75(1):20-4. PubMed ID: 10502420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.